Invesco Ltd. Has $189.16 Million Stock Holdings in Avantor, Inc. $AVTR

Key Points

• Invesco Ltd. increased its stake in Avantor, Inc. by 19.3%, owning approximately 11.67 million shares valued at $189.16 million by the end of the first quarter.
• Several institutional investors, including The Manufacturers Life Insurance Company and KBC Group NV, have significantly increased their positions in Avantor, reflecting strong institutional interest in the company.
• Avantor reported a quarterly earnings miss with an EPS of $0.24, falling short of analysts' expectations of $0.25, and the company experienced a 1.1% decline in revenue compared to the same quarter last year.

Invesco Ltd. raised its holdings in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 19.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,669,411 shares of the company's stock after acquiring an additional 1,884,273 shares during the quarter. Invesco Ltd. owned approximately 1.71% of Avantor worth $189,161,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Avantor by 10.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,257 shares of the company's stock valued at $132,000 after buying an additional 592 shares in the last quarter. American Trust grew its stake in shares of Avantor by 4.5% in the 4th quarter. American Trust now owns 15,198 shares of the company's stock valued at $320,000 after buying an additional 658 shares in the last quarter. Nissay Asset Management Corp Japan ADV grew its stake in shares of Avantor by 1.0% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 82,523 shares of the company's stock valued at $1,767,000 after buying an additional 857 shares in the last quarter. Portside Wealth Group LLC grew its stake in shares of Avantor by 9.0% in the 1st quarter. Portside Wealth Group LLC now owns 10,673 shares of the company's stock valued at $173,000 after buying an additional 882 shares in the last quarter. Finally, Signaturefd LLC grew its stake in shares of Avantor by 19.8% in the 1st quarter. Signaturefd LLC now owns 5,470 shares of the company's stock valued at $89,000 after buying an additional 904 shares in the last quarter. Institutional investors own 95.08% of the company's stock.

Avantor Stock Performance

Shares of NYSE AVTR traded up $0.05 during trading hours on Monday, reaching $12.98. The stock had a trading volume of 2,743,041 shares, compared to its average volume of 10,655,789. The business's fifty day moving average is $13.19 and its two-hundred day moving average is $14.70. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.98 and a quick ratio of 0.67. The company has a market cap of $8.85 billion, a price-to-earnings ratio of 13.10, a PEG ratio of 1.46 and a beta of 0.96. Avantor, Inc. has a twelve month low of $10.82 and a twelve month high of $27.83.

Avantor (NYSE:AVTR - Get Free Report) last issued its earnings results on Friday, August 1st. The company reported $0.24 EPS for the quarter, missing analysts' consensus estimates of $0.25 by ($0.01). The firm had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Avantor had a net margin of 10.31% and a return on equity of 11.39%. The business's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.25 earnings per share. As a group, research analysts expect that Avantor, Inc. will post 1.06 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on AVTR shares. Jefferies Financial Group reaffirmed a "hold" rating on shares of Avantor in a research report on Friday, August 1st. Wells Fargo & Company decreased their target price on Avantor from $19.00 to $16.00 and set an "overweight" rating for the company in a research report on Monday, August 4th. JPMorgan Chase & Co. decreased their target price on Avantor from $17.00 to $14.00 and set an "overweight" rating for the company in a research report on Monday, August 4th. Barclays reaffirmed an "overweight" rating and set a $13.00 target price (down previously from $15.00) on shares of Avantor in a research report on Monday, August 4th. Finally, Robert W. Baird decreased their target price on Avantor from $18.00 to $15.00 and set an "outperform" rating for the company in a research report on Monday, August 4th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $15.50.

Insiders Place Their Bets

In related news, Director Gregory L. Summe acquired 30,000 shares of the business's stock in a transaction on Friday, May 23rd. The stock was bought at an average cost of $12.50 per share, with a total value of $375,000.00. Following the completion of the acquisition, the director owned 100,000 shares in the company, valued at $1,250,000. The trade was a 42.86% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Steven W. Eck sold 3,476 shares of Avantor stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $11.39, for a total value of $39,591.64. Following the transaction, the chief accounting officer directly owned 55,068 shares of the company's stock, valued at approximately $627,224.52. The trade was a 5.94% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.